Pro/Con: Should patients taking SGLT2 inhibitors be dropped from the elective surgical program?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new and potent drug class for the treatment of type 2 diabetes mellitus. Inhibition of the SGLT2 protein in the proximal tubule of the kidney leads to increased excretion of glucose and sodium, resulting in weight loss reduction in blood pressure and hemoglobin A1c levels. Extensive clinical trials have demonstrated impactful cardiovascular and kidney-protective effects, even in patients without diabetes. The US Food and Drug Administration (FDA) approved SGLT2i for treating heart failure and chronic kidney disease for patients without diabetes, leading to an increased prescription rate of this drug class.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Peter Wohlrab, Martin H. Bernardi Tags: Pro and Con Source Type: research
More News: Anesthesia | Anesthesiology | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Heart | Heart Failure | SGLT2 Inhibitors | Sodium | Urology & Nephrology | Weight Loss